A new study published in Cellular & Molecular Immunology describes how a lesser-known TWEAK–Fn14 signaling route can interact with Tumor Necrosis Factor (TNF) to amplify inflammation in rheumatoid arthritis. The researchers used human tissues and rat data to map the molecular communications behind the inflammatory response and found that simultaneous activity of TWEAK–Fn14 and TNF produces a sharp increase in inflammation.
Blocking the Fn14 receptor reduced the inflammatory surge typically caused by TNF, suggesting the TWEAK–Fn14 route can act as a "back-door" that permits inflammation to continue when the main TNF pathway is blocked. Salah-uddin Ahmed, professor and associate dean and the paper's corresponding author, and first author Farheen Shaikh report these results as a form of "crosstalk" between signaling pathways.
The finding may help explain why roughly 30% to 40% of patients do not respond to TNF inhibitors and why some responders lose effectiveness over time. TNF inhibitors are approved for several conditions and the market was estimated at about $25 billion in 2024. As a next step, Ahmed plans to test therapeutic strategies that target both inflammatory pathways together or focus on Fn14 alone, and the team says further study of Fn14 could shed light on other autoimmune illnesses where TNF is involved.
Difficult words
- signaling — process of sending messages between cells
- receptor — cell protein that binds specific molecules
- inflammation — body's response causing redness and swelling
- crosstalk — interaction where one pathway affects another"crosstalk"
- inhibitor — substance or drug that reduces biological activityinhibitors
- pathway — series of actions inside cells or bodypathways
- autoimmune — disease caused by immune system attacking the body
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- How might therapies that target both TNF and the TWEAK–Fn14 route change treatment results for patients? Give reasons.
- What possible challenges or risks could appear if doctors block two inflammatory pathways at once?
- How could studying Fn14 lead to better understanding of other autoimmune illnesses where TNF is involved?
Related articles
Many pesticides used in Latin America are banned in the EU
A study found that many active pesticide ingredients allowed on major crops in eight Latin American countries are banned or not authorised in the EU. The researchers examined public approval records up to December 2020 and warn of health risks.